Table 3. Survival analyses.

A)	PFS	Median survival (months, 95% CI)		Median survival ratio (high/low)
	p-value*	low methylation	high methylation		HR (95% CI)**
CST6	0.009	11.4 (6.2–NE)	2.0 (1.3–NE)	0.175	4.1 (1.3–12.6)
LAD1	0.004	11.4 (3.0–NE)	2.0 (1.7–NE)	0.175	6.4 (1.6–26.0)
miR-124-3	0.339	11.9 (6.2–NE)	2.6 (1.7–11.5)	0.218	1.8 (0.5–6.6)
miR-9-1	0.319	4.6 (1.3–NE)	2.7 (1.8–NE)	0.587	1.7 (0.6–4.7)
B)	OS	Median survival (months, 95% CI)		Median survival ratio (high/low)
	p-value *	low methylation	high methylation		HR (95% CI) **
CST6	0.011	22.9 (13.1–NE)	3.4 (2.5–NE)	0.148	4.1 (13.0–13.4)
LAD1	0.043	16.4 (11.7–NE)	3.4 (3.0–NE)	0.207	2.9 (1.0–8.6)
miR-124-3	0.786	13.7 (11.7–NE)	9.8 (3.2–29.8)	0.715	0.8 (0.2–3.1)
miR-9-1	0.624	12.4 (3.4–NE)	14.4 (3.2–NE)	1.161	1.3 (0.5–3.6)

Abbreviations:

PFS: Progression-free survival.

OS: Overall survival.

NE: not estimable.

HR: Hazard ratio.

CI: Confidence interval.

*: log-rank statistical analysis.

**: Univariate Cox regression for purpose of comparision.

low methylation cutoff <8.75.

high methylation cutoff ≥8.75.